NobleStitch EL STITCH Trial is a PFO Comparative Trial

Last updated: October 30, 2023
Sponsor: Nobles Medical Technologies II Inc
Overall Status: Suspended

Phase

N/A

Condition

Stroke

Thrombosis

Blood Clots

Treatment

Amplatzer PFO Occluder

NobleStitch™EL Suture Mediated Closure System

Clinical Study ID

NCT04339699
748824-0819
  • Ages 18-60
  • All Genders

Study Summary

STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch™ EL versus FDA-approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent Ischemic stroke.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for theduration of the study
  • Male or female ages 18 - 60 years old
  • A PFO and a Cryptogenic Stroke verified by a neurologist
  • Stroke is defined as an acute focal neurological deficit, presumed to be due to focalischemia, and either:
  • Symptoms persisting ≥24 hours, or
  • Symptoms persisting <24 hours with Magnetic Resonance or CT findings of a new,neuroanatomical relevant infarct
  • Cryptogenic stroke was defined as a stroke of unknown cause
  • Prolonged cardiac rhythm monitoring (recommended 30 days and not less than 24 hoursrequired)
  • Intra and extracranial artery imaging: Magnetic Resonance Angiography, CT angiography,or contrast angiography, or contrast angiography or echocardiography of the carotidarteries to rule out ischemic stroke associated with atherosclerotic plaque, arterialdissection, or other vascular diseases. (The aortic arch may also be evaluated byTEE).
  • Hypercoagulable state assessment to rule out an underlying hypercoagulable state

Exclusion

Exclusion Criteria:

  • Female participant who is pregnant, lactating or planning a pregnancy during thecourse of the study
  • Age <18 or > 60 years of age
  • Previous myocardial infarction or unstable angina within 6 months
  • Clinically significant mitral or aortic valve stenosis or severe regurgitation
  • Left Ventricular Ejection Fraction <50 percent
  • Progressive neurological dysfunction or reduced life expectancy
  • Contrast allergy
  • Atrial Septal Defect (baseline left to right shunt assessed by TEE or other congenitalheart diseases
  • Active Endocarditis
  • Perspective participants with known causes of Ischemic Stroke
  • Arterial dissection
  • Contraindicated or unsuitable for antiplatelet agents or oral anticoagulants
  • Perspective participants with prosthetic heart valves
  • Uncontrolled diabetes Mellitus
  • Pulmonary hypertension
  • Uncontrolled systemic hypertension
  • Intracranial pathology
  • Neurological deficits not due to stroke that may affect neurologic assessments
  • Active autoimmune disease
  • Active infection
  • Alcohol and/or drug abuse
  • A requirement for chronic anticoagulation therapy that cannot be discontinued
  • Anatomic features (inability to achieve vascular access)

Study Design

Total Participants: 640
Treatment Group(s): 2
Primary Treatment: Amplatzer PFO Occluder
Phase:
Study Start date:
January 01, 2021
Estimated Completion Date:
June 30, 2027

Study Description

To demonstrate the non-inferiority of the NobleStitch™ EL with medical management in both safety and effectiveness compared to the FDA-approved Amplatzer Occluder with medical management for PFO Closure.

To demonstrate that the NobleStitch EL does not increase the incidence of ischemic stroke compared to published medical management data.

Connect with a study center

  • Ospedale S. Eugenio

    Roma, Lazio 00144
    Italy

    Site Not Available

  • TMC HealthCare

    Tucson, Arizona 85712
    United States

    Site Not Available

  • Tampa General Hospital

    Tampa, Florida 33606
    United States

    Active - Recruiting

  • USF/Tampa General Hospital

    Tampa, Florida 33606
    United States

    Site Not Available

  • Lehigh Valley Health Network

    Allentown, Pennsylvania 18103
    United States

    Site Not Available

  • Inova Structural Heart Disease Program - Fairfax

    Fairfax, Virginia 22042
    United States

    Site Not Available

  • Inova Cardiovascular Institute

    Falls Church, Virginia 22042
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.